---
title: "Faro’s $37.3M Series B: Agentic AI for Clinical Development"
description: "Faro AI raised $37.3M Series B co-led by Merck Global Health Innovation Fund and S32, with General Catalyst returning. Platform used by 6 of the world’s 10 largest pharma companies. Structured clinical-intent data — not chat-on-PDFs."
date: 2026-08-26T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "healthtech", "artificial-intelligence"]
source: https://venturecapitaltracker.com/2026-faro-37-3m-series-b-merck-s32-general-catalyst
---

# Faro’s $37.3M Series B: Agentic AI for Clinical Development

> Faro AI raised $37.3M Series B co-led by Merck Global Health Innovation Fund and S32, with General Catalyst returning. Platform used by 6 of the world’s 10 largest pharma companies. Structured clinical-intent data — not chat-on-PDFs.

**Faro AI** closed a **$37.3 million Series B** on **August 26, 2026**, co-led by **Merck Global Health Innovation Fund** and **S32**. [General Catalyst](/fund/general-catalyst) returned with Northpond, Polaris, PTX, and Zetta; Ankona joined. Merck GHI and S32 have **no** `/fund/` pages here.

**Unexpected truth:** the company says it already sits inside **six of the ten largest** pharma companies — then raises a mid-size Series B to turn protocol-centric structure into **agentic workflows**, not another drafting demo.

This page is for healthtech scouts and founders selling into regulated development orgs. Last verified **August 31, 2026**. Primary: Faro’s own Series B letter.

## Five-minute decision

| If you need… | Verdict |
| --- | --- |
| What happened | **Funded.** $37.3M Series B. Merck GHI + S32 co-lead. **No valuation.** |
| What Faro is | Structured clinical-development data model + agent layer starting at the protocol. |
| Whether it is shipping | **Yes** — 6/10 largest pharma (company). |
| Whether to diligence | **Yes**, if clinical-dev AI must survive regulated multi-system workflows. |

**Investigate further when:** your buyer already drafts protocols in siloed tools and feels the downstream breakage.

**Wait or pass when:** you need ARR, retention, or a disclosed mark.

## What happened

| Field | Detail |
| --- | --- |
| Company | Faro AI (ex-Faro Health; San Diego) |
| Round | **$37.3M Series B** · Aug 26, 2026 |
| Co-leads | Merck Global Health Innovation Fund, S32 |
| Returning | General Catalyst, Northpond, Polaris, PTX, Zetta |
| New | Ankona Capital |
| Traction claim | **6 of top 10** global pharma (company) |

## Who uses it — and why this syndicate

**Users:** large-pharma clinical development teams spanning study design, protocol authoring, study build, execution, data flows, and review. Faro’s letter: customers want agents that understand **why** an endpoint was chosen and what that implies for schedules, data collection, downstream systems, and regulatory constraints — not a paragraph rewriter.

**Why Merck GHI + S32 + GC fit:**

- **Merck GHI** is strategic capital with pharma-native diligence; Mike Morgan’s quote frames agentic AI as quality + time, not novelty.
- **S32** co-leading signals multi-stage healthcare infrastructure appetite.
- **General Catalyst** already underwrote the earlier Faro Health thesis; returning is portfolio continuity as the brand shifts Health → AI.

Likely reason Faro raises from them: enterprise pharma sales cycles need patient capital and a strategic that understands ICH/regulated process risk — not a consumer-AI growth fund.

## Why now

Biopharma is moving from AI-as-isolated-task to AI-across-workflows. Faro spent years on proprietary clinical development data models so agents can reason over **intent**, with documents as outputs rather than the system of record. Series B funds expanding agent capabilities on that substrate.

## What is not proven

- No valuation, ARR, NRR, or named logos beyond the 6/10 claim.
- “Largest pharma” definition not footnoted.
- Agentic workflow depth vs protocol-authoring assistance is company-described, not independently audited.

## Competitive map

| Category | Examples | Faro contrast |
| --- | --- | --- |
| Protocol drafting AI | Document copilots | Faro claims structured intent across the continuum |
| eClinical / EDC suites | Incumbent trial software | Faro positions as AI layer, not full replacement |
| Health data infra (Metriport et al.) | Interop / records | Different job: development program design vs care delivery data |

## Implication

The open question is whether Faro becomes the **system of intent** for clinical development or stays a high-end protocol tool with agent wrappers. Diligence the 6/10 claim with reference calls before treating Series B as category victory.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** August 31, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.